PTC Therapeutics expects EMA committee opinion on AADC deficiency gene therapy in May

Apr. 14, 2022 9:27 AM ETPTC Therapeutics, Inc. (PTCT)By: Anuron Mitra, SA News Editor
  • Biopharmaceutical company PTC Therapeutics (NASDAQ:PTCT) on Thursday said it has completed procedural meetings for its gene therapy treatment for (AADC) deficiency with the European Union drug regulator's Committee for Advanced Therapies (CAT).
  • The CAT will provide its opinion for adoption of the therapy to the European Union drug regulator's Committee for Medicinal Products for Human Use in May.
  • PTCT's gene therapy treats aromatic L-amino acid decarboxylase (AADC) deficiency, a rare and fatal genetic disorder that typically causes severe disability from the first months and years of life.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.